KR101926625B1 - Contact lens for aiding antismoking - Google Patents

Abstract

The present invention relates to a contact lens for smoking cessation assistance.
It is an object of the present invention to provide a contact lens having a smoking-aid function.
Another object of the present invention is to provide a contact lens manufacturing method which does not cause problems of partial polymerization, uncopolymerization, and over-polymerization during polymerization of contact lenses, does not deform the lens, and has excellent transparency of the lens.
According to the present invention as described above, the contact lens is provided with a smoking-aid aid in the contact lens, thereby providing the contact lens for smoking cessation assistance. In addition, the contact lens for smoking cessation assistance has an effect of assisting reduction of smoking need and successful cessation of smoking when a smoker wears it. There is provided a contact lens which is free from the problem of partial polymerization, non-polymerization, and over-polymerization during polymerization of a contact lens, and which does not deform the lens and has excellent transparency of the lens by sequentially raising the polymerization reaction temperature in the production of the contact lens. .

Description

{CONTACT LENS FOR AIDING ANTISMOKING}

The present invention relates to a contact lens for smoking cessation assistance.

Contact lenses were initially aimed at vision correction, but they were developed for a variety of purposes, such as treatment and cosmetics.

The contact lens for vision correction corrects nearsightedness, primordiality, astigmatism, and the like, corrects the refractive error by correcting the visual acuity by focusing the light coming into the eye. Recently, it has been used in correction of myopia, which is also used for correction of myopia. I wear a lens to wear the lens to flatten the surface of the cornea so that the lens can be removed even during the day.

Therapeutic contact lenses help to treat cornea by protecting the cornea from swelling due to blinking of the eye. In addition, to overcome the disadvantage that eye drop has low bioavailability, it is used to treat eye disease by transferring drug to the eye when the lens is worn including the drug in the lens. The therapeutic contact lens is used for the treatment of ocular diseases such as hyperkeratosis, dry eye syndrome, corneal abrasion, corneal epithelial erosion, keratitis, corneal edema, corneal ulcer and corneal hypertrophy.

Because smoking is dependent on nicotine, spontaneous cessation of smokers is very difficult and long-term cigarette smoking can cause serious health problems. Tobacco contains more than 7,000 chemicals, of which 100 are toxic and 70 are the cause of cancer.

Most smokers consider smoking to be a simple personal habit rather than a chronic illness that needs treatment, and try to quit smoking at will. However, the success rate is significantly lower when attempting to quit smoking without counseling and helping the smoking cessation aid. Smoking cessation therapy is recommended for all smokers who wish to quit smoking. Nicotine replacement therapy (NRT: patches, gum, candy, and spray) is the first drug that is approved by the FDA and recommended for use in the US and Europe. Bupropion and bar Varenicline is being used.

It is an object of the present invention to provide a contact lens having a smoking-aid function.

Another object of the present invention is to provide a contact lens manufacturing method which does not cause problems of partial polymerization, uncopolymerization, and over-polymerization during polymerization of contact lenses, does not deform the lens, and has excellent transparency of the lens.

In order to achieve the above object, the present invention provides a contact lens for smoking cessation including a smoking cessation aid.

The smoking cessation aid may comprise at least one of Varenicline and Bupropion.

The present invention also provides a method of manufacturing a contact lens for smoking cessation comprising stirring a mixture containing an acrylic monomer, a hydrophilic monomer, a crosslinking agent, an initiator and a smoking cessation aid, and polymerizing the stirred mixture.

The acrylic monomer is at least one of 2-HEMA (2-hydroxyethylmethacrylate), 2-HEA (2-hydroxyethylacrylate), HPA (hydroxypropyllacrylate) and HPMA (hydroxypropylmethacrylate).

The hydrophilic monomer is NVP (N-vinyl-2-pyrrolidone).

The crosslinking agent may be selected from the group consisting of ethylene glycol dimethacrylate (EGDMA), trimethylolpropane trimethacrylate, triallylisocyanurate, diethylene glycol diacrylate and neopentyl glycol And is at least one of neopentyl glycol diacrylate.

The initiator may be selected from the group consisting of AIBN (azobisisobutyronitrile), BPO (benzoyl peroxide), azobis (2,4-dimethylpentanenitrile), azobis (azobis), methylbutyronitrile ), Azobis (cyclohexanecarbonitrile), di-tert-butyl-peroxide, tert-butyl-perbenzoate and caliper sulfate And Kali persulfate.

The smoking cessation aid is characterized in that it is at least one of Varenicline and Bupropion.

Wherein the mixture further comprises at least one of MMA (methylmethacrylate) and GMA (glycidyl methacrylate), which are methacrylate monomers.

Wherein the mixture contains from 93 to 97% by weight of an acrylic monomer, from 1 to 3% by weight of a hydrophilic monomer, from 0.3 to 0.7% by weight of a crosslinking agent, from 0.1 to 0.3% by weight of an initiator, from 0.03 to 0.07% By weight based on the total weight of the composition.

The step of polymerizing the stirred mixture is characterized in that the polymerization reaction temperature is raised sequentially at 60 to 70 ° C, 75 to 85 ° C, and 105 to 115 ° C.

According to the present invention as described above, the contact lens is provided with a smoking-aid aid in the contact lens, thereby providing the contact lens for smoking cessation assistance.

In addition, the contact lens for smoking cessation assistance has an effect of assisting reduction of smoking need and successful cessation of smoking when a smoker wears it.

There is provided a contact lens which is free from the problem of partial polymerization, non-polymerization, and over-polymerization during polymerization of a contact lens, and which does not deform the lens and has excellent transparency of the lens by sequentially raising the polymerization reaction temperature in the production of the contact lens. .

Figure 1 shows the structure of a smoking cessation aid, Varenicline.
Figure 2 shows the structure of the smoking cessation aid bupropion.

Hereinafter, the present invention will be described in detail.

The contact lens for smoking cessation assistance according to one embodiment of the present invention includes a smoking cessation aid.

It is preferably at least one of the above-mentioned Varenicline and Bupropion.

Varenicline has been approved by the FDA as Chantix in the United States in 2006 as a smoking cessation aid with a chemical structure as shown in Figure 1 and approved by NICE in 2007 in Champix, UK. The mechanism of action of barrenicin is a selective α4β2 nicotine receptor partial agonist, which acts similarly to nicotine and continuously releases mesalimbic dopamine. Because of the persistent secretion of dopamine, smoking cessation helps reduce smoking cessation while reducing the compensatory effect of nicotine.

Bupropion is a smoking cessation aid having the chemical structure as shown in FIG. 2, and is recommended to be used when failure to treat NRT (Nicotine replacement therapy) fails or when there is a feeling of refusal to use nicotine. In addition, bupropion is more effective against smoking than placebo in smokers with heart disease or respiratory diseases such as COPD. The NRT is a smoking cessation aid used in many countries. It is slowly absorbed through the skin in the form of a patch to reduce the withdrawal symptoms caused by smoking cessation. There are five types of NRTs: gum, candy, sour cream, and spray inhaler.

A method of manufacturing a contact lens for smoking cessation assistance according to another aspect of the present invention includes stirring a mixture containing an acrylic monomer, a hydrophilic monomer, a crosslinking agent, an initiator and a smoking cessation aid, and polymerizing the stirred mixture.

The acrylic monomer is preferably at least one of 2-hydroxyethylmethacrylate (2-HEMA), 2-hydroxyethyl acrylate (2-HEA), hydroxypropyllacrylate (HPA) and hydroxypropylmethacrylate (HPMA). By selecting at least one of the acrylic monomers, the heat resistance is improved and a contact lens having an improved water content can be obtained. Further, when the polymer is polymerized in a mold for a contact lens, transparency is good and unevenness such as uneven coloring is solved.

The hydrophilic monomer is preferably NVP (N-vinyl-2-pyrrolidone).

The NVP is a hydrophilic monomer having a vinyl group and is mainly used to increase the water content. However, when only NVP is used, there is a drawback that the strength is low and the adsorbability is high, so that it is copolymerized with other monomers.

The crosslinking agent may be selected from the group consisting of ethylene glycol dimethacrylate (EGDMA), trimethylolpropane trimethacrylate, triallylisocyanurate, diethylene glycol diacrylate and neopentyl glycol It is preferably at least one of neopentyl glycol diacrylate.

The initiator may be selected from the group consisting of AIBN (azobisisobutyronitrile), BPO (benzoyl peroxide), azobis (2,4-dimethylpentanenitrile), azobis (azobis), methylbutyronitrile ), Azobis (cyclohexanecarbonitrile), di-tert-butyl-peroxide, tert-butyl-perbenzoate and caliper sulfate (Kali persulfate).

The smoking cessation aid is preferably at least one of Varenicline and Bupropion.

Preferably, the mixture further comprises at least one of methacrylate-based monomers such as MMA (methylmethacrylate) and GMA (glycidyl methacrylate).

When the acrylic monomer is used alone, the strength is lowered. Therefore, a methacrylate-based monomer is used together to enhance durability. The methacrylate monomer increases the water content of the contact lens and improves the biocompatibility by making the contact lens negative.

Wherein the mixture contains from 93 to 97% by weight of an acrylic monomer, from 1 to 3% by weight of a hydrophilic monomer, from 0.3 to 0.7% by weight of a crosslinking agent, from 0.1 to 0.3% by weight of an initiator, from 0.03 to 0.07% By weight.

When the amount of the crosslinking agent is less than 0.3% by weight, the bonding force during polymerization is low, which is undesirable because deformation occurs in the manufacture of contact lenses. If the amount of the initiator is less than 0.1% by weight, molding of the contact lens is difficult, and if it exceeds 0.3% by weight, a large amount of residue is formed and the feeling of wearing of the contact lens is lowered. In the case of the smoking cessation aid, if the amount is less than 0.03% by weight, the effect of smoking cessation is insignificant. If the content is more than 0.07% by weight, the increase in the effect of smoking cessation is insignificant.

delete

When the content of the methacrylate monomer is less than 1% by weight, the elasticity of the contact lens is low. When the content of the methacrylate monomer is more than 3% by weight, the prepared contact lens becomes hard and the wearability is remarkably deteriorated.

The step of polymerizing the stirred mixture is preferably carried out in such a manner that the polymerization reaction temperature is elevated successively at 60 to 70 캜 (primary temperature), 75 to 85 캜 (secondary temperature) and 105 to 115 캜 (tertiary temperature) .

By sequentially raising the polymerization reaction temperature, the frequency of occurrence of partial polymerization, non-polymerization, and over-coupling, which was a problem in conventional contact lens production, is reduced, and lens deformation hardly occurs. In addition, the contact lenses produced by sequentially raising the polymerization reaction temperature are soft, elastic, and excellent in transparency.

At the first reaction temperature, the polymerization reaction starts and proceeds, and at the second reaction temperature, polymerization reaction is actively performed to form all the structures. At the tertiary reaction temperature, the formed structure is hardened and stabilized.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these examples are for illustrative purposes only and that the scope of the present invention is not construed as being limited by these examples.

Example  1. Manufacture of contact lenses for smoking cessation

To produce a contact lens comprising a smoking cessation aid,

(Specific gravity: 0.94, mass conversion: 9 g; 0.78% by weight) as a polymerization initiator, 1,000 ml of a 2-hydroxyethyl methacrylate (2-HEMA) (specific gravity 1.1, 1,100 g; 95.3% by weight in terms of mass), methyl methacrylate (Specific gravity: 1.04, mass conversion: 21 g; 1.8 wt%), N, N-vinyl-2-pyrrolidone (NVP), 15 ml of glycidyl methacrylate (GMA, specific gravity: 1.073, (0.17% by weight) of azobisisobutylonitrile (AIBN) and 0.6 g (0.05% by weight) of bupropion were mixed to prepare a mixture of 12 g of ethylene glycol diacrylate (TEGDA) (specific gravity 1.125, Lt; / RTI >

The stirred mixture was injected into a mold for contact lens molding. The molding mold was placed in an oven and the temperature of the oven was gradually increased. First, the oven temperature is maintained at 60 to 70 DEG C (primary temperature) for 20 to 40 minutes. Also, the oven temperature was maintained at 75 to 85 캜 (secondary temperature) for 20 to 40 minutes, and then the oven temperature was maintained at 105 to 115 캜 (third temperature) for 80 to 10 minutes. As described above, the oven temperature was successively increased to complete the polymerization reaction, thereby producing the contact lens for smoking cessation assistance.

After the mold with the lens molded in the oven was taken out, the front surface of the lens was lathed and polished. The contact lens produced from the mold was removed, and the foreign substance such as the abrasive was washed. The cleaned contact lenses were sealed and packed with saline.

Example 2 . Survey of wearing comfort of contact lens for smoking cessation aid

The fit feeling of the contact lens for smoking aid assistance produced in Example 1 was examined and it is shown in Table 1. The contact lenses of the smoking cigarette contact lenses were surveyed by 100 smokers. The survey subjects consisted of 30 persons in their 20s and 20 persons in their 30s, and 20 persons in their 30s.

Survey of wearing comfort of contact lens for smoking cessation aid Subject Inconvenience Slight inconvenience ease A twenties man 30 people One 4 25 A twenties woman 30 people 0 4 26 A thirties man 20 people 2 2 16 Thirties woman 20 people 2 One 17

According to the results of the wearing feelings of the contact lenses for smoking cessation assistance prepared in Example 1, 84 (84%) out of 100 subjects answered that they feel comfortable wearing a contact lens for smoking cessation assistance.

Example 3 . Smoking cessation effect of contact lens for smoking cessation aid

3-1. Investigation of reduction effect of smoking needs of contact lens for smoking cessation aid

The smoking reduction effect of the contact lens for smoking cessation assistance produced in Example 1 was examined and shown in Table 2. The smokers 'smokers' cigarette smoking reduction effect of contact lens for smoking cessation was surveyed by 100 persons. The survey subjects were 20 persons, 20 persons in each of male and female, and 20 persons in male and female in 30s. do.

Investigation of reduction effect of smoking needs of contact lens for smoking cessation aid Subject No meaning at all Slightly meaningful In effect Very effective A twenties man 30 people 3 5 14 8 A twenties woman 30 people 4 4 11 11 A thirties man 20 people 2 4 8 6 Thirties woman 20 people 2 6 7 5

According to the result of investigation of reduction effect of smoking needs of the contact lens for smoking cessation assistance prepared in Example 1, 70 (70%) out of 100 subjects answered that they have a cigarette smoking suppressing effect when wearing a contact lens for smoking cessation assistance. Of the respondents who answered that they had a cigarette smoking suppression effect when wearing a contact lens for smoking cessation assistance, 30 responded 'very effective' to suppress cigarette smoking when wearing a contact lens for smoking cessation assistance.

3-1. To investigate the effect of smoking cessation when using a contact lens for smoking cessation aid

The smoking cessation effect of the contact lens for smoking cessation assistance produced in Example 1 was examined and is shown in Table 3. The effect of smoking cessation aid contact lens was investigated in 30 smokers. The subject to be researched is composed of 10 persons in each of 10th, 20th, and 30th classes, which are the main use layers of contact lenses, and the sex and the smoking period are not considered.

30 smokers were asked to wear a contact lens for smoking cessation for 8 weeks.

Smoking cessation effect of contact lens for smoking cessation aid Subject 1 parking 2 parking 4 parking 8 parking failure Teenager 10 people 8 One 0 One 0 20's 10 people 7 One 2 0 0 30s 10 people 7 0 One One One

According to the investigation result of the smoking need reducing effect of the contact lens for smoking cessation assistance produced in Example 1, 29 out of the total 30 subjects were successfully quit smoking. Particularly, in the first week of the survey, 22 out of 30 subjects were successfully quit smoking.

Therefore, it was found that smoking cessation was significantly reduced when wearing the contact lens for smoking cessation assistance prepared in Example 1, and most of the subjects were able to quit after 4 weeks of wearing the cigarette.

Having described specific portions of the present invention in detail, those skilled in the art will appreciate that these specific embodiments are merely preferred embodiments and that the scope of the present invention is not limited thereby. something to do. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.

Claims (12)

delete delete 2-hydroxyethyl methacrylate, N-vinyl-2-pyrrolidone, azobisisobutyronitrile, bupropion as a smoking aid, methyl methacrylate, glycidyl methacrylate and tetraethylene glycol di Stirring the mixture comprising acrylate and
And polymerizing the stirred mixture,
Wherein the step of polymerizing the agitated mixture is carried out by sequentially performing primary polymerization at 60 to 70 ° C, secondary polymerization at 75 to 85 ° C, and tertiary polymerization at 105 to 115 ° C / RTI >
delete delete delete delete delete delete The method of claim 3,
The mixture contained 95.3% by weight of 2-hydroxyethyl methacrylate, 1.8% by weight of N-vinyl-2-pyrrolidone, 0.5% by weight of tetraethylene glycol diacrylate, 0.17% by weight of azobisisobutyronitrile, , 0.05% by weight of bupropion, 0.78% by weight of methyl methacrylate and 1.4% by weight of glycidyl methacrylate. delete delete

Images